These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 33240265)

  • 1. Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art.
    Zhang Y; Chen Y; Meng Z
    Front Immunol; 2020; 11():577442. PubMed ID: 33240265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).
    Pinheiro MM; Fabbri A; Infante M
    Immunotherapy; 2021 Jun; 13(9):753-765. PubMed ID: 33906375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulation and immunotherapeutics of COVID-19.
    Garg SS; Sharma A; Gupta J
    Clin Immunol; 2021 Oct; 231():108842. PubMed ID: 34461289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients.
    Bonam SR; Kaveri SV; Sakuntabhai A; Gilardin L; Bayry J
    Cell Rep Med; 2020 May; 1(2):100016. PubMed ID: 32562483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention.
    Hall MW; Joshi I; Leal L; Ooi EE
    Clin Infect Dis; 2022 Jan; 74(1):144-148. PubMed ID: 32604407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
    Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR
    Front Immunol; 2022; 13():888897. PubMed ID: 35663932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges.
    Pourgholaminejad A; Pahlavanneshan S; Basiri M
    Scand J Immunol; 2022 Feb; 95(2):e13131. PubMed ID: 34936112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.
    Song N; Wakimoto H; Rossignoli F; Bhere D; Ciccocioppo R; Chen KS; Khalsa JK; Mastrolia I; Samarelli AV; Dominici M; Shah K
    Stem Cells; 2021 Jun; 39(6):707-722. PubMed ID: 33586320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 and immunomodulation in IBD.
    Neurath MF
    Gut; 2020 Jul; 69(7):1335-1342. PubMed ID: 32303609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation and Regeneration Properties of Dental Pulp Stem Cells: A Potential Therapy to Treat Coronavirus Disease 2019.
    Zayed M; Iohara K
    Cell Transplant; 2020; 29():963689720952089. PubMed ID: 32830527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine storm induced by SARS-CoV-2.
    Song P; Li W; Xie J; Hou Y; You C
    Clin Chim Acta; 2020 Oct; 509():280-287. PubMed ID: 32531256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm.
    Pum A; Ennemoser M; Adage T; Kungl AJ
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33445810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm.
    Chau AS; Weber AG; Maria NI; Narain S; Liu A; Hajizadeh N; Malhotra P; Bloom O; Marder G; Kaplan B
    Arthritis Rheumatol; 2021 Jan; 73(1):23-35. PubMed ID: 32929876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection.
    Copaescu A; Smibert O; Gibson A; Phillips EJ; Trubiano JA
    J Allergy Clin Immunol; 2020 Sep; 146(3):518-534.e1. PubMed ID: 32896310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
    Atluri S; Manchikanti L; Hirsch JA
    Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
    Quirch M; Lee J; Rehman S
    J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy.
    Verma YK; Verma R; Tyagi N; Behl A; Kumar S; Gangenahalli GU
    Stem Cell Rev Rep; 2021 Feb; 17(1):113-131. PubMed ID: 32920752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm.
    Peng X; Wang Y; Xi X; Jia Y; Tian J; Yu B; Tian J
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):231-247. PubMed ID: 33404925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.